Soligenix, Inc. SNGX
Soligenix, Inc. (Nasdaq: SNGX) is a dermatology drug developer. Its lead program, SGX302 (synthetic hypericin sodium, photodynamic therapy), is in Phase 2 for mild-to-moderate psoriasis.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| SGX942 (dusquetide) | oral mucositis in head and neck cancer (Phase 3 missed primary endpoint Dec 2020; second Phase 3 needed, contingent on partner, not enrolling; SciClone holds China-region rights) | protein/peptide | Phase 3 |
| HyBryte (SGX301) | cutaneous T-cell lymphoma (second Phase 3 FLASH2 halted for futility April 2026; program terminated June 2026) | small molecule | Phase 3 |
| SGX302 (synthetic hypericin + visible light) | mild-to-moderate psoriasis (Phase 2a ongoing; Cohort 3 gel formulation reported Dec 2025) | small molecule | Phase 2 |
| SGX945 (dusquetide) | aphthous ulcers in Behcet's disease (Phase 2a completed July 2025) | protein/peptide | Phase 2 |
| RiVax | ricin toxin vaccine (Phase 1a/1b/1c completed; contingent on government funding) | vaccine | Phase 1 |
| Filovirus vaccines (EBOV, SUDV, BDBV, MARV) and ThermoVax platform | Ebola/Marburg biodefense vaccines | vaccine | Pre-clinical |
| SGX943 (dusquetide) | antibiotic-resistant and emerging infectious disease | protein/peptide | Pre-clinical |
Recent results and decisions
- Apr 28, 2026missed Phase 3 FLASH2 interim efficacy analysis: Data Monitoring Committee recommended halting the study for futility; no HyBryte signal seen at 18 weeks.
Under the terms of the interim analysis, the study was recommended to halt for futility.
Filing - Feb 12, 2026positive Open-label investigator-initiated study: 75% of patients achieved Treatment Success after 18 weeks, with 3 of 8 evaluable patients achieving a complete response.
Following 18 weeks of continuous “real world” treatment, 75% of patients achieved “Treatment Success,” with three of the eight evaluable patients achieving a complete response over the course of the study.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.